MASLD相关肝细胞癌中低FIB-4的患病率:一项多中心研究
这项多中心队列研究纳入2008年1月至2023年8月七个国际中心613例MASLD相关肝细胞癌成人(33%女性),评估低FIB-4比例。无已知肝硬化者235例(38%),其中62例(26%)FIB-4低;低FIB-4者肿瘤总直径中位数更大(p<0.001)、血清甲胎蛋白中位数更低(p=0.005)。作者认为超过四分之一无肝硬化MASLD相关肝细胞癌患者FIB-4低,拟议临床诊疗路径可能无法识别这些人以进一步评估。
要点
- 613例MASLD相关肝细胞癌中235例(38%)无已知肝硬化。
- 无已知肝硬化者中62例(26%)FIB-4低(<1.3,或年龄>65岁时<2)。
- 低FIB-4者肿瘤总直径中位数更大、血清甲胎蛋白中位数更低。
核心结论
- 超过四分之一无肝硬化的MASLD相关肝细胞癌患者FIB-4低,拟议临床诊疗路径可能无法识别这些人以进一步评估。
研究设计与样本
- 这项队列研究纳入2008年1月至2023年8月澳大利亚、印度、日本、韩国、新加坡和美国七个国际中心的613例连续成人(33%女性)MASLD相关肝细胞癌患者。
主要发现
- 平均(±SD)年龄71(±11)岁,平均(±SD)体重指数27(±7)kg/m2。
- 235例参与者(38%)无已知肝硬化。
- FIB-4中位数为3.90(IQR 2.42-6.42)。
- 78例参与者(13%)FIB-4低;无已知肝硬化者(n=235)中62例(26%)FIB-4低。
- 与无低FIB-4的参与者相比,低FIB-4者肿瘤总直径中位数更大(p<0.001)、血清甲胎蛋白中位数更低(p=0.005)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major society guidelines recommend the fibrosis-4 index (FIB-4) as the initial step to risk stratifying people with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to evaluate the proportion of people with MASLD-related hepatocellular carcinoma (HCC) and a low FIB-4. METHODS: This cohort study included 613 consecutive adults (33% female) diagnosed with MASLD-related HCC from January 2008 to August 2023 at seven international centres in Australia, India, Japan, South Korea, Singapore and the United States. The primary objective was to determine the proportion of participants with a low FIB-4, defined as FIB-4 < 1.3, or < 2 if age > 65 years, in people without cirrhosis. RESULTS: The mean (±SD) age and body mass index were 71 (±11) years and 27 (±7) kg/m2, respectively. Overall, 235 participants (38%) did not have known cirrhosis. The median FIB-4 was 3.90 (IQR 2.42-6.42). A total of 78 participants (13%) had a low FIB-4. Among participants without known cirrhosis (n = 235), 62 participants (26%) had a low FIB-4. Participants with a low FIB-4 had larger median total tumour diameter (p < 0.001) and lower median serum alpha-fetoprotein (p = 0.005), compared to participants without a low FIB-4. Cirrhosis was associated with lower odds of low FIB-4, but not other factors such as male sex, type 2 diabetes, or obesity. CONCLUSION: More than a quarter of those with MASLD-related HCC without cirrhosis have a low FIB-4. The proposed clinical care pathways may not identify these people for further evaluation.
引用
- Tan DJH, Tamaki N, Kim BK, et al. Prevalence of Low FIB-4 in MASLD-Related Hepatocellular Carcinoma: A Multicentre Study. Aliment Pharmacol Ther. 2024. PMID: 39462858. doi:10.1111/apt.18346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。